Genentech history

Ibandronic acid injection uses
Ibandronic acid how to take
Ibandronate dose

•

Genentech

American biotechnology corporation

Key people

Company type	Subsidiary
Traded as	Nasdaq: DNA
Industry	Biotechnology
Founded	1976; 49 years ago (1976)
Founders	Robert A. Swanson and Herbert Boyer
Headquarters	South San Francisco, California, United States
Products	Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Ocrevus, Polivy, Tecentriq, Xofluza, Hemlibra, Venclexta, Esbriet, Cotellic, Alecensa, Zelboraf, Nutropin, Actemra, Lucentis, Xolair, Activase, Cathflo Activase, Xeloda, Boniva, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax
Revenue	$26.4 billion (2020)^[4]
Number of employees	13,539 (July 2021)
Parent	Roche
Website	gene.com
Footnotes / references ^[5]

Genentech, Inc. is an American biotechnologycorporation headquartered in South San Francisco, California, wholly owned by the Sw

•

Bisphosphonates in multiple myeloma: an updated network meta‐analysis

Abstract

Background

Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane review first published in 2002 and previously updated in 2010 and 2012.

Objectives

To assess the evidence related to benefits and harms associated with use of various types of bisphosphonates (aminobisphosphonates versus non‐aminobisphosphonates) in the management of patients with MM. Our primary objective was to determine whether adding bisphosphonates to standard therapy in MM improves OS and progression‐free survival (PFS), and decreases skeletal‐related morbidity. Our secondary objectives were to determine the effects of bisphosphonates on pain, quality of life, incidence of hypercalcemia, incidence of bisphosphonate‐related gastrointestinal toxicities, osteonecrosis of

•

Ibandronic acid

Chemical compound

Pharmaceutical compound

License data

Trade names	Boniva, Bonviva, Bondronat, others
AHFS/Drugs.com	Monograph
Pregnancy category
Routes of administration	By mouth, intravenous
ATC code
Legal status
Bioavailability	0.6%
Protein binding	90.9 to 99.5% (concentration-dependent)
Metabolism	Nil
Elimination half-life	10 to 60 hours
Excretion	Kidney
IUPAC name Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard(EPA)
ECHA InfoCard	100.214.537
Formula	C₉H₂₃NO₇P₂
Molar mass	319.231 g·mol⁻¹
3D model (JSmol)
SMILES O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
InChI InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)^Y Key:MPBVHIBUJCELCL-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Iban